MEDICAL DEVICE USER FEES SOUGHT BY FDA IN FY 1997 BUDGET REQUEST TO WHITE HOUSE; FDA DEPUTY COMMISSIONER SCHULTZ REITERATES FDA SUPPORT FOR ADDITIVE FEES
This article was originally published in The Gray Sheet
Executive Summary
FDA is seeking about $23.7 mil. in additive device user fees in the fiscal year 1997 (beginning Oct. 1) budget request pending at the Office of Management and Budget. The level of device user fee funding, which would enable the addition of 109 full-time equivalent staff positions to work on improving device review times, is the same that FDA unsuccessfully proposed in its fiscal 1996 budget request ("The Gray Sheet" Feb. 13, 1995, p. 6).
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.